A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers

Clinical Rheumatology

Volumn 32, Issue 5, 2013, Pages 665-670

  Pomirleanu, Cristina ^a,b   Ancuta, Codrina ^a,b   Miu, Smaranda ^a,b   Chirieac, Rodica ^a,b  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Clinical Rehabilitation Hospital   (Romania)

Author keywords

Anti TNF agents; Established rheumatoid arthritis; Low disease activity; Predictors; Remission

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CONFIDENCE INTERVAL; DAS28; DISEASE ACTIVITY; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; FEMALE; HUMANS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PREDNISOLONE; PROSPECTIVE STUDIES; QUESTIONNAIRES; REMISSION INDUCTION; RHEUMATOID FACTOR; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878728100     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2146-6     Document Type: Article

References (24)

1. Luqmani R, Hennell S, Estrach C, Birrell F, Bosworth A, Davenport G, Fokke C, Goodson N, Jeffreson P, Lamb E, Mohammed R, Oliver S, Stableford Z, Walsh D, Washbrook C, Webb F, British Society for Rheumatology, British Health Professionals in Rheumatology Standards Guidelines and Audit Working Group (2006) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford) 45:1167-1169
2. Bykerk V, Keystone E (2005) What are the goals and principles of management in the early treatment of rheumatoid arthritis. Best Pract Res ClinRheumatol 19:147-161
3. Fransen J, Moens HB, Speyer I, van Riel PL (2005) Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomized controlled trial. Ann Rheum Dis 64:1294-1298
4. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ et al (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer assisted management in early rheumatoid arthritis (camera, an open-label strategy trial). Ann Rheum Dis 66:1443-1449
5. Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F et al (2011) Group for respect of ethics and excellence in science (grees). Biomarkers and personalized medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis 70(10):1713-1718
6. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W et al (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10:1-229, iii-iv, xi-xiii
7. Marotte H, Miossec P (2010) Biomarkers for prediction of TNFα blockers response in rheumatoid arthritis. Joint Bone Spine 77:297-05
8. Mader R, Keystone E (2007) Optimizing treatment with biologics. J Rheumatol Suppl 80:16-24
9. Erickson AR, Mikuls TR (2007) Switching anti-TNF-alpha agents: what is the evidence. CurrRheumatol Rep 9(5):416-420
10. Bolosiu H, Ionescu R, Chirieac R, Georgescu L, Rednic S, Suta M, et al. (2011) Ghidul de tratament al poliartriteireumatoide. RevistaRomanǎ de Reumatologie vol. xx nr. 1; 36-53.
11. van Gestel AM, Prevoo ML, van Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 39:34-40
12. Katchamart W, Johnson S, Lin H, Phumethum V, Salliot C, Bombardier C (2010) Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res 62:1128-1143
13. Vazquez I, Graell E, Gratacos J, Canete JD, Vinas O, Ercilla MG et al (2007) Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting. ClinExpRheumatol 25:231-238
14. Forslind K, Hafstrom I, Ahlmen M, Svensson B (2007) The BARFOT Study Group. Sex: a major predictor of remission in early rheumatoid arthritis. Ann Rheum Dis 66:46-52
15. Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Saez I, Unnebrink K, Kary S et al (2008) Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 59:32-41
16. Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, Geborek P (2008) Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish arthritis treatment group register. Rheumatology (Oxford) 47:495-499
17. Verstappen SM, van Albada-Kuipers GA, Bijlsma JW, Blaauw AA, Schenk Y, Haanen HC et al (2005) A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 64:38-43
18. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D et al (2007) Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-α blockers: the GISEA study. J Rheumatol 34:1670-1673
19. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J (2002) For the FIN-RACo Trial Group. Delay to institution of therapy and induction of remission using singledrug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46:894-898
20. Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register (2006) Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45:1558-1565
21. Van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P (2007) For the TEMPO Study Investigators. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 56:3928-3939
22. Molenaar ET, Voskuyl AE, van der Horst-Bruinsma IE, Schreuder GM, Zanelli E, Dijkmans BA (2002) Influence of HLA polymorphism on persistent remission in rheumatoid arthritis. Ann Rheum Dis 61:351-353
23. Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register (2006) Comparison of the response to infliximab or etanerceptmonotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:1786-1794
24. Liang GC, Cordero M, Dyer A, Chang RW (2005) Current tumor necrosis factor-α inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis. J Rheumatol 32:1662-1665